Tannic Acid Inhibits CaMKII-β Kinase Activity In Vitro and Displays Preclinical Anti-Tumor Activity in Ovarian Cancer Models
Ovarian cancer (OC) is characterized by delayed clinical diagnosis, intrinsic/acquired platinum chemoresistance, and a high postoperative recurrence rate, highlighting an unmet clinical need for new targeted therapeutic strategies. Herein, we integrated pan-cancer transcriptomic profiling, clinical tissue immunohistochemistry, siRNA-mediated gene silencing, co-immunoprecipitation, structure-based virtual ligand screening, in vitro kinase activity assays, cellular viability functional assays, and SK-OV-3 xenograft mouse models to preliminarily reveal that CaMKII-β may mediate OC progression and characterize the anti-tumor potency of tannic acid. We preliminarily found that CaMKII-β is upregulated in OC patient tissues, and its elevated expression correlates with unfavorable overall survival. Genetic depletion of CaMKII-β attenuated OC cell viability both in vitro and in vivo via interfering with RAS-related signaling and suppressing downstream PI3K, AKT, and NF-κB transcriptional signaling cascades. Structure-based virtual screening identified tannic acid as a candidate CaMKII-β inhibitor with an IC50 value of 217 nM. Functional cellular assays demonstrated that tannic acid suppresses OC cell viability in a dose-dependent manner, accompanied by reduced phosphorylation of PI3K, AKT, and NF-κB, while the total protein levels of these signaling intermediates remain unaltered. In vivo intraperitoneal injection of tannic acid impeded the growth of SK-OV-3 xenograft tumors without inducing measurable systemic weight loss in host mice. In summary, CaMKII-β may contribute to malignant progression of OC through its association with RAS-related signaling, and tannic acid shows pre-clinical preliminary anti-tumor activity associated with CaMKII-β-related signaling in OC. Further mechanistic validation, pharmacokinetic, toxicological, and clinically relevant in vivo studies are required to evaluate its translational potential.
Authors
- Jin Chang (ORCID: https://orcid.org/0000-0001-7449-4080)
- 忠 旭山
- Ruqi Liang
- Yizhao Chen (ORCID: https://orcid.org/0000-0002-7470-4196)
- Yaru Miao (ORCID: https://orcid.org/0009-0007-3298-6168)
Institutions
- Shanxi Medical University (CN)
- Shanxi University (CN)
- Taiyuan University of Technology (CN)
Publication Details
- Journal
- Cells
- Published
- 2026-11-12
- DOI
- https://doi.org/10.3390/cells15222059
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Taiyuan University of Technology